incretin hormone glp-1 Targeting both receptors together for a new generation of diabetes therapies Frontiers | Variation in responses
Description
Gerstenberg, M

The safety profile of tirzepatide was consistent with GLP-1 receptor agonists

However, to date, there is only one randomized clinical trial of GLP-1 RAs (the ELIXA study) evaluating major cardiovascular events as their primary outcomes, and in this study, a neutral cardiovascular effect of lixisenatide was observed in high-risk diabetic subjects
The dosage of tirzepatide was gradually increased every 4 weeks until the assigned dose was reached

[DOI] [PubMed] [Google Scholar] 44.Grill H.J

If you are considering GLP-1 treatment, ThinEra offers medically supervised weight loss through telehealth with consistent clinical guidance and transparent care standards
